NSCLC metastatic/molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 01/04/2021)

EGFR
MARIPOSA (Janssen Research & Development) (1st line)
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Papillon (Janssen) (1st line)
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

ZENITH20 Poziotinib (Spectrum) (1st and 2nd line)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(cohort 3 closed, cohort 4-5-6-7 open)

INSIGHT-2 (Merck) (2nd line)
A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC).

ALK
Currently no open trials

KRAS
CJDQ443A2101 (Novartis) (2nd and further line)
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation. 

CodeBreak 200 (Amgen) (2nd and 3rd line after chemo- and immunotherapy) 
A phase 3 study to compare AMG510 with docetaxel in NSCLC subjects with KRAS p.G12C mutation
(currently on hold)


RET
LIBRETTO-431 (Eli Lilly) (1st line)
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer.

BRAF
LXH254, LTT462 (Novartis) (end-line)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer.
(only cohort for BRAF open)

BFAST (Roche) (1st line)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort E open)

C-MET
CINC280J12201 (Novartis) (1ste line)
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations.

Geometry III (Novartis) (2nd and 3rd line after chemo- and immunotherapy)
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation.

ROS1
TRIDENT-1 (TurningPoint) (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements.

HER2
ZENITH20 Poziotinib (Spectrum) (1st and 2nd line)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(cohort 3 closed, cohort 4-5-6-7 open)

NTRK
TRIDENT-1 (TurningPoint)  (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements.

3th line (all mutations)
ImmunoSABR (Academic)
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer.